Ampersand Biomedicines

Ampersand Biomedicines is a Flagship Pioneering-founded biotech developing a novel class of targeted therapeutics called AND-Body Therapeutics. Its proprietary AND Platform combines a computational 'Address Map' of human biology with modular engineering to create drugs that localize to diseased tissue and activate a therapeutic payload only there. The company is in the preclinical stage, targeting a broad range of diseases across multiple organs with its versatile platform technology.

The AND Platform: A proprietary, computationally powered system for creating programmable, multi-specific therapeutics. It consists of an 'Address Map' (multi-omics database for target identification), a 'Navigate' engine for AI-guided binder discovery, and a 'Determine' module for engineering conditionally active drugs that localize to disease sites and activate a therapeutic payload.

Ampersand competes in the broad field of targeted drug delivery, including companies developing antibody-drug conjugates (ADCs), tissue-specific gene therapies, and other tissue-targeting platforms. Its differentiation lies in its systematic, computation-driven 'Address Map' and its goal to fully decouple targeting from therapeutic action, a more modular approach than most existing technologies.